

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4985655

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
TEVA PHARMACEUTICAL INDUSTRIES, LTD.	04/09/2018
RECEIVING PARTY DATA	
Name:	CLEXIO BIOSCIENCES LTD.
Street Address:	21 NAHUM HAFTZADI STREET
City:	JERUSALEM
State/Country:	ISRAEL
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15780420
CORRESPONDENCE DATA	
Fax Number:	(215)568-3439
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	215-568-3100
Email:	assignments@woodcock.com
Correspondent Name:	BAKER & HOSTETLER LLP
Address Line 1:	CIRA CENTRE 12TH FLOOR
Address Line 2:	2929 ARCH STREET
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19104-2891
ATTORNEY DOCKET NUMBER:	111748.000038
NAME OF SUBMITTER:	VALERIE CHICCHI
SIGNATURE:	/Valerie Chicchi/
DATE SIGNED:	05/31/2018
Total Attachments: 5	
source=SIGNED_ASSIGNMENT_TEVA_TO_CLEXIO#page1.tif	
source=SIGNED_ASSIGNMENT_TEVA_TO_CLEXIO#page2.tif	
source=SIGNED_ASSIGNMENT_TEVA_TO_CLEXIO#page3.tif	
source=SIGNED_ASSIGNMENT_TEVA_TO_CLEXIO#page4.tif	
source=SIGNED_ASSIGNMENT_TEVA_TO_CLEXIO#page5.tif	

PATENT ASSIGNMENT

WHEREAS, Teva Pharmaceutical Industries Ltd., a company incorporated under the laws of the State of Israel (herein: the "Assignor"), has made certain inventions that are subject of the patents and/or patent applications set forth in **Appendix A** to this assignment, which inventions and patents and patent applications will be referred to herein as the "Inventions", the "Patents" and the "Applications", respectively; and

WHEREAS, Clexio Biosciences Ltd. (herein: the "Assignee"), a company incorporated under the laws of the State of Israel, with offices at 21 Nahum Haftzadi Street, Jerusalem, Israel, is desirous of obtaining the entire right, title and interest in, to and under the Inventions, the Patents and the Applications and the Assignor is ready, willing and able to assign to the Assignee all such right, title and interest.

NOW THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor does hereby assign to the Assignee, its successors, legal representatives and assigns, and the Assignee hereby accepts, all right, title and interest in, to and under the Inventions, the Patents and the Applications, including, without limitation, all rights, powers, privileges and immunities arising thereunder or conferred thereby including the right to sue for past infringement, and all divisions, renewals and continuations thereof, and any and all applications that may be filed thereon in any jurisdictions, and all patents that may be granted thereon, and all reissues or extensions thereof, and all divisions, renewals and continuations thereof, and all patents that may be granted thereon and all extensions and reissues thereof, together with any and all rights of priority relating to the Inventions and the Applications and any applications filed or patents granted thereon.

AND THE ASSIGNOR HEREBY authorizes and requests any official of any country or jurisdiction, whose duty it is to issue and record patents on the Applications, to issue and record the same to and in the name of the Assignee, its successors, legal representative and assign, in accordance with the terms of this instrument.

AND THE ASSIGNOR HEREBY covenants and agrees that it has full right to convey all interests and ownership rights in the Inventions, the Patents and the Applications.

AND THE ASSIGNOR FURTHER HEREBY covenants and agrees that it will communicate and relay to the Assignee, its successors, legal representative and assigns, any facts and documents known to it representing the Inventions, testify to any legal proceeding, and that it and its employees shall sign all lawful papers, execute all divisional, continuing, reissue and foreign applications, make all rightful oaths, and generally do everything possible to aid the Assignee, its successors, legal representative and assigns, to vest title in the Inventions, the Patents and Applications and related foreign rights in the Assignee and its successors and assigns and to obtain and enforce proper protection for the Inventions in all countries.

AND THE ASSIGNOR hereby irrevocably appoints the Assignee and its duly authorized officers and agents as attorney in fact for the Assignor, to act on its behalf to execute and file any documents and to do all other lawfully permitted acts to further the purposes of this Assignment, including without limitation the prosecution and issuance of letters patent, with the same legal force and effect as if executed by me.

Teva Pharmaceutical Industries Ltd.

By: 
Sharon F. Hausdorff, Ph.D.
VP and Chief Patent Counsel

By: 
Lillian Rae Glazer, PhD
Sr. Director, Associate General Patent Counsel, CNS
Global Specialty IP

Appendix A

Detomidine -- Assigned Patents

Teva Ref.	Cty	Status	Applicant	Application No	Application Date	Grant No	Grant Date	Expiry	Product	Title
FRZ044-PCT	WO	Pending	Teva Pharmaceutical Industries Ltd.	PCT/US18/012579	05 Jan 2018				TEV-90118, DETOMIDINE	Topical Formulations Including Alpha-adrenergic Agonists

Caines -- Assigned Patents

Teva Ref.	Cty	Status	Applicant	Application No	Application Date	Grant No	Grant Date	Expiry	Product	Title
FRZ116-P1	US	Pending	Teva Pharmaceutical Industries Ltd.	62/579,987	01 Nov 2017			01 nov 2018	TEV-573, LIDOCAINE	Impregnated Textiles And Methods Of Their Use And Preparation
FRZ116-P2	US	Pending	Teva Pharmaceutical Industries Ltd.	62/583,835	09 Nov 2017			09 nov 2018	TEV-573, LIDOCAINE	Impregnated Textiles And Methods Of Their Use And Preparation

OLAR – Assigned Patents

Teva Ref.	Cty	Status	Applicant	Application No	Application Date	Grant No	Grant Date	Expiry	Product	Title
BSL001-PCT-EP	EPw	Published	Teva Pharmaceutical Industries Ltd.	16806298.2	02 dez 2016				LEVODOPA, GASTRIC RETENTIVE	Devices and Methods for Preparing Gastroretentive Dosage Forms
BSL001-US	US	Published	Teva Pharmaceutical Industries Ltd.	15/368,274	02 dez 2016				LEVODOPA, GASTRIC RETENTIVE	Devices and Methods for Preparing Gastroretentive Dosage Forms
BSL001-PCT-WO	WO	Published	Teva Pharmaceutical Industries Ltd.	PCT/IB06/057331	02 dez 2016				LEVODOPA, GASTRIC RETENTIVE	Devices and Methods for Preparing Gastroretentive Dosage Forms
PTV041-A-PCT-AU	AUw	Pending	Teva Pharmaceutical Industries Ltd.	2015271808	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Dosage Form
PTV041-A-PCT-BR	BRw	Pending	Teva Pharmaceutical Industries Ltd.	11201602818.0.2	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Dosage Form
PTV041-A-PCT-CA	CAw	Pending	Teva Pharmaceutical Industries Ltd.	AWAITED	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Dosage Form
PTV041-A-PCT-CL	CLw	Pending	Teva Pharmaceutical Industries Ltd.	201603055	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Dosage Form
PTV041-A-PCT-CN	CNw	Published	Teva Pharmaceutical Industries Ltd.	20158004076.0.8	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Dosage Form
PTV041-A-PCT-EP	EPw	Pending	Teva Pharmaceutical Industries Ltd.	15803601.2	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Dosage Form
PTV041-A-PCT-CN-HK	HK	Pending	Teva Pharmaceutical Industries Ltd.	17106915.0	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Drug Delivery System
PTV041-A-PCT-IL	ILw	Published	Teva Pharmaceutical Industries Ltd.	248.939	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Dosage Form

PTV041-A-PCT-JP	JPw	Pending	Teva Pharmaceutical Industries Ltd.	2016-570968	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Dosage Form
PTV041-A-PCT-KR	KRw	Pending	Teva Pharmaceutical Industries Ltd.	10-2016-7037099	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Dosage Form
PTV041-A-PCT-MX	MXw	Pending	Teva Pharmaceutical Industries Ltd.	MX/A/2016/015891	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Dosage Form
PTV041-A-PCT-NZ	NZw	Pending	Teva Pharmaceutical Industries Ltd.	726457	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Dosage Form
PTV041-A-PCT-RU	RUw	Pending	Teva Pharmaceutical Industries Ltd.	2016151697	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Dosage Form
PTV041-A-US	US	Published	Teva Pharmaceutical Industries Ltd.	14/728,986	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Drug Delivery System
PTV041-A-PCT	WO	National	Teva Pharmaceutical Industries Ltd.	PCT/US15/033850	02 jun 2015			Expired. National applications filed	GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Dosage Form
PTV041-A-PCT-ZA	ZAW	Pending	Teva Pharmaceutical Industries Ltd.	2016/08018	02 jun 2015				GASTRIC RETENTIVE, LEVODOPA	Expandable Gastroretentive Dosage Form
PTV116-PCT	WO	Published	Teva Pharmaceutical Industries Ltd.	PCT/US16/064439	01 dez 2016				BIODEGRADABLE, GASTRIC RETENTIVE	Novel Biodegradable Formulation for Gastric Retentive Dosage Form
PTV149-CA	CA	Pending	Teva Pharmaceutical Industries Ltd.	2,950,373	02 dez 2016				GRDF	Gastric Retentive Dosage Forms - Expandable Closing Triangle
PTV149-PCT	WO	Pending	Teva Pharmaceutical Industries Ltd.	PCT/US17/064417	04 dez 2017				GRDF	Gastric Retentive Dosage Forms - Expandable Closing Triangle
PTV239-P1	US	Pending	Teva Pharmaceutical Industries Ltd.	62/594,257	04 dez 2017			04 dez 2018	OLAR, GRDF	Gastric Residence System

PATENT